2024
EP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer
Ermer T, Kim S, Goldberg S, Zolfaghari E, Blasberg J, Boffa D, Herbst R, Politi K, Schalper K, Dacic S, Woodard G. EP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2024, 19: s543-s544. DOI: 10.1016/j.jtho.2024.09.1007.Peer-Reviewed Original ResearchThe Proposed Ninth Edition TNM Classification of Lung Cancer
Detterbeck F, Woodard G, Bader A, Dacic S, Grant M, Park H, Tanoue L. The Proposed Ninth Edition TNM Classification of Lung Cancer. CHEST Journal 2024, 166: 882-895. PMID: 38885896, DOI: 10.1016/j.chest.2024.05.026.Peer-Reviewed Original Research
2023
So Now We Know—Reflections on the Extent of Resection for Stage I Lung Cancer
Detterbeck F, Ely S, Udelsman B, Blasberg J, Boffa D, Dhanasopon A, Mase V, Woodard G. So Now We Know—Reflections on the Extent of Resection for Stage I Lung Cancer. Clinical Lung Cancer 2023, 25: e113-e123. PMID: 38310034, DOI: 10.1016/j.cllc.2023.12.007.Peer-Reviewed Original ResearchStage I lung cancerI lung cancerSublobar resectionRecurrence-free survivalHealthy patientsLung cancerRecent trialsInadequate resection marginsLarge recent trialsAdditional randomized trialsHigh-level evidenceOverall survival differenceExtent of resectionLong-term outcomesLong-term resultsHigh locoregional recurrenceAspects of patientsLesser resectionsLocoregional recurrencePerioperative morbidityIntraoperative detailsLung functionResection extentResection marginsPostoperative changesImpact of the COVID-19 Pandemic on Lung Cancer Screening Processes in a Northeast Tertiary Health Care Network
Udelsman B, Detterbeck F, Tanoue L, Mase V, Boffa D, Blasberg J, Dhanasopon A, Ely S, Mazzarelli L, Bader A, Woodard G. Impact of the COVID-19 Pandemic on Lung Cancer Screening Processes in a Northeast Tertiary Health Care Network. Journal Of Computer Assisted Tomography 2023, 48: 222-225. PMID: 37832536, DOI: 10.1097/rct.0000000000001549.Peer-Reviewed Original ResearchHealth care networkLung cancer screening processLung cancer screening programsCare networkCancer screening programsCoronavirus disease 2019 (COVID-19) pandemicComputed tomography scanCOVID-19 hospitalizationCOVID-19 surgeCancer screening processDisease 2019 pandemicLung cancer diagnosisHealth care systemAverage hospitalizationRadiology databaseLung cancerTomography scanScreening programCare systemCancer diagnosisMonthsHospitalizationCOVID-19COVID-19 pandemicPandemicComparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas
Woodard G, Ding V, Cho C, Brand N, Kratz J, Jones K, Jablons D. Comparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas. Lung Cancer 2023, 180: 107211. PMID: 37121213, PMCID: PMC10900430, DOI: 10.1016/j.lungcan.2023.107211.Peer-Reviewed Original ResearchConceptsInvasive portionDriver mutationsSolid adenocarcinomaLung cancer driver mutationsNext-generation sequencingWarrants further studyLobar resectionClinical characteristicsSurgical databaseAsian patientsInvasive cancerPoor prognosisLung cancerLung lesionsInvasive componentInvasive solid tumorsNormal lungLepidicStage IPromising biomarkerSolid tumorsCancer developmentSame time periodGenes SPP1Gene expressionThe Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer
Grant M, Woodard G, Goldberg S. The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer. Hematology/Oncology Clinics Of North America 2023, 37: 513-531. PMID: 37024389, DOI: 10.1016/j.hoc.2023.02.003.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLung cancerMetastatic non-small cell lung cancerResectable non-small cell lung cancerImmuno-oncology agentsHistologic classification systemUnited States FoodResectable tumorsSystemic therapyDriver alterationsDrug AdministrationStates FoodSystemic managementPatientsTherapyCancerEvolving roleClassification systemNTRKHER2TumorsKRASEGFRBRAF
2022
EP14.05-021 Promising Long-Term Survival after Surgical Resection of Early Stage Small Cell Lung Cancer in a Modern Single-Center Cohort
Ely S, Udelsman B, Homer R, Dhanasopon A, Woodard G. EP14.05-021 Promising Long-Term Survival after Surgical Resection of Early Stage Small Cell Lung Cancer in a Modern Single-Center Cohort. Journal Of Thoracic Oncology 2022, 17: s552-s553. DOI: 10.1016/j.jtho.2022.07.996.Peer-Reviewed Original ResearchA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation— part 1: a guide to decision-making
Detterbeck FC, Blasberg JD, Woodard GA, Decker RH, Kumbasar U, Park HS, Mase VJ, Bade BC, Li AX, Brandt WS, Madoff DC. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation— part 1: a guide to decision-making. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813719, PMCID: PMC9264102, DOI: 10.21037/jtd-21-1823.Peer-Reviewed Original ResearchLong-term outcomesIndividual patientsHealthy patientsLung cancerFavorable tumorsStage I lung cancerBetter long-term outcomesI lung cancerStage I NSCLCOlder patientsPatient selectionPoint of careSurgical approachClinical careEffect modifiersTreatment selectionPatientsTreatment approachesPatient valuesClinical judgmentSystematic reviewRelevant outcomesLong-term differencesAvailable evidenceShort-term differencesA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 2: systematic review of evidence regarding resection extent in generally healthy patients
Detterbeck FC, Mase VJ, Li AX, Kumbasar U, Bade BC, Park HS, Decker RH, Madoff DC, Woodard GA, Brandt WS, Blasberg JD. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 2: systematic review of evidence regarding resection extent in generally healthy patients. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813747, PMCID: PMC9264068, DOI: 10.21037/jtd-21-1824.Peer-Reviewed Original ResearchNon-randomized comparisonHealthy patientsResection extentIndividual patientsSystematic reviewStage I lung cancerI lung cancerStage I NSCLCCharacteristics of patientsPulmonary function testsLong-term outcomesRisk of recurrenceVideo-assisted approachSublobar resectionWedge resectionRandomized trialsFunction testsLung cancerResidual confoundingEffect modifiersShort-term benefitsLobectomyPatientsPubMed systematic reviewMargin distanceA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 3: systematic review of evidence regarding surgery in compromised patients or specific tumors
Bade BC, Blasberg JD, Mase VJ, Kumbasar U, Li AX, Park HS, Decker RH, Madoff DC, Brandt WS, Woodard GA, Detterbeck FC. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 3: systematic review of evidence regarding surgery in compromised patients or specific tumors. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813753, PMCID: PMC9264070, DOI: 10.21037/jtd-21-1825.Peer-Reviewed Original ResearchLimited pulmonary reserveLong-term outcomesResection extentNon-randomized comparisonPulmonary reserveOlder patientsIndividual patientsFavorable tumorsSystematic reviewStage I lung cancerFavorable long-term outcomeI lung cancerScreen-detected tumorsStage I NSCLCCharacteristics of patientsShort-term outcomesLesser resectionsPerioperative mortalityPulmonary functionSublobar resectionWedge resectionPatient selectionRandomized trialsLung cancerResidual confoundingA guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation
Park HS, Detterbeck FC, Madoff DC, Bade BC, Kumbasar U, Mase VJ, Li AX, Blasberg JD, Woodard GA, Brandt WS, Decker RH. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813762, PMCID: PMC9264060, DOI: 10.21037/jtd-21-1826.Peer-Reviewed Original ResearchLong-term outcomesNon-randomized comparisonIndividual patientsSystematic reviewStage I lung cancerI lung cancerCharacteristics of patientsStage I NSCLCPulmonary function testsMinority of patientsShort-term outcomesStereotactic body radiotherapyThermal ablationLate toxicityPulmonary functionRandomized trialsFunction testsAdjusted comparisonsBody radiotherapyLung cancerResidual confoundingEffect modifiersShort-term benefitsPatientsPubMed systematic review
2021
Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay
Gupta AR, Woodard GA, Jablons DM, Mann MJ, Kratz JR. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay. Future Oncology 2021, 17: 4785-4795. PMID: 34435876, PMCID: PMC9039775, DOI: 10.2217/fon-2021-0517.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinogenesisCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantClinical Decision-MakingDatasets as TopicDisease-Free SurvivalGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLung NeoplasmsMolecular Diagnostic TechniquesNeoplasm Recurrence, LocalNeoplasm StagingPneumonectomyProspective StudiesReal-Time Polymerase Chain ReactionRisk AssessmentConceptsCell lung cancerUndetectable metastasesLung cancerCell lung cancer patientsDisease-free survivalAdjuvant chemotherapy decisionsTime of surgeryLung cancer patientsSurgical resectionComplete resectionProspective studyCancer patientsChemotherapy decisionsResectionMolecular assaysPatientsPredictive benefitMetastasisCancerMortalityQuantitative PCRExpression profilesEarly stagesAssaysSurgery
2020
Everybody Must Get Scanned? Molecular Risk Stratification May Limit the Need for CT Surveillance Following Surgical Resection of Early-Stage Non-Squamous, Non-Small Cell Lung Cancer
Hamilton B, Haro G, Woodard G, Sheu B, Kratz J, Mann M, Jablons D. Everybody Must Get Scanned? Molecular Risk Stratification May Limit the Need for CT Surveillance Following Surgical Resection of Early-Stage Non-Squamous, Non-Small Cell Lung Cancer. 2020, a7693-a7693. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7693.Peer-Reviewed Original Research
2019
Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer
Haro GJ, Sheu B, Cook NR, Woodard GA, Mann MJ, Kratz JR. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e1917062. PMID: 31808928, PMCID: PMC6902768, DOI: 10.1001/jamanetworkopen.2019.17062.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerTNM staging systemDisease-free survivalHigh-risk patientsCell lung cancerStaging systemEighth editionSurgical resectionLung cancerConventional TNMPrognostic classifierNonsquamous non-small cell lung cancerQuaternary care medical centerDisease-free survival ratesHigh molecular riskSurvival 3 yearsEarly-stage diseaseConventional TNM stagingCritical unmet needCohort studyPrimary outcomeConsecutive seriesTNM stagingMolecular riskConcordance index
2018
Scientific Advances and New Frontiers in Mesothelioma Therapeutics
Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R. Scientific Advances and New Frontiers in Mesothelioma Therapeutics. Journal Of Thoracic Oncology 2018, 13: 1269-1283. PMID: 29966799, PMCID: PMC6643278, DOI: 10.1016/j.jtho.2018.06.011.Peer-Reviewed Original Research
2017
Management of Lung Cancer Invading the Superior Sulcus
Kratz JR, Woodard G, Jablons DM. Management of Lung Cancer Invading the Superior Sulcus. Thoracic Surgery Clinics 2017, 27: 149-157. PMID: 28363369, DOI: 10.1016/j.thorsurg.2017.01.008.Peer-Reviewed Original ResearchConceptsSuperior sulcus tumorsLung cancerComplete surgical resectionFormidable therapeutic challengeInitial therapeutic effortsBimodality therapyTrimodality therapySurgical resectionTherapeutic challengeSuperior sulcusTreatment approachesTherapeutic effortsCurrent standardTherapyHigh rateTumorsCancerResectionRelapseRadiotherapyMortalityCarePancoastOA19.06 Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non-Small Cell Lung Cancer
Woodard G, Crockard J, Zoon-Besselink C, Kratz J, Gubens M, Jahan T, Blakely C, Jones K, Mann M, Jablons D. OA19.06 Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2017, 12: s320. DOI: 10.1016/j.jtho.2016.11.341.Peer-Reviewed Original Research
2016
FAIM2, as a novel diagnostic maker and a potential therapeutic target for small-cell lung cancer and atypical carcinoid
Kang HC, Kim JI, Chang HK, Woodard G, Choi YS, Ku JL, Jablons DM, Kim IJ. FAIM2, as a novel diagnostic maker and a potential therapeutic target for small-cell lung cancer and atypical carcinoid. Scientific Reports 2016, 6: 34022. PMID: 27677402, PMCID: PMC5039724, DOI: 10.1038/srep34022.Peer-Reviewed Original ResearchSmall cell lung cancerCell lung cancerAtypical carcinoidLung cancerTypical carcinoidNE tumorsSCLC cellsTherapeutic targetNon-small cell lung cancerDiagnostic markerLung NE tumorsNE tumor markersWorse clinical outcomesLung neuroendocrine tumorsPresence of necrosisPotential therapeutic targetNew therapeutic targetsUseful diagnostic markerNumber of mitosesBetter diagnostic criteriaFas apoptosis pathwayNE cancersClinical outcomesNeuroendocrine tumorsFAIM2 expressionGli promotes epithelial-mesenchymal transition in human lung adenocarcinomas
Li H, Yue D, Jin JQ, Woodard GA, Tolani B, Luh TM, Giroux-Leprieur E, Mo M, Chen Z, Che J, Zhang Z, Zhou Y, Wang L, Hao X, Jablons D, Wang C, He B. Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas. Oncotarget 2016, 5: 80415-80425. PMID: 27533453, PMCID: PMC5348330, DOI: 10.18632/oncotarget.11246.Peer-Reviewed Original ResearchMeSH KeywordsA549 CellsAdenocarcinomaAdenocarcinoma of LungAnimalsAntigens, CDAntineoplastic AgentsCadherinsCell MovementEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHedgehog ProteinsHumansLung NeoplasmsMaleMice, NudeMiddle AgedNeoplasm InvasivenessSignal TransductionSmoothened ReceptorTime FactorsTumor BurdenXenograft Model Antitumor AssaysZinc Finger Protein GLI1ConceptsEpithelial-mesenchymal transitionLung adenocarcinomaE-cadherin expressionTumor growthLung adenocarcinoma metastasisPotential therapeutic targetInhibition of GLICell migrationAdenocarcinoma metastasisLung cancerInvasion/metastasisTumor invasion/metastasisIndependent cohortGLI inhibitorsSmall molecule inhibitorsTherapeutic targetAdenocarcinomaHuman lungTherapeutic agentsMetastasisCell invasionWound healingCommon typeRole of GliMolecule inhibitorsConsensus Report of the 2015 Weinman International Conference on Mesothelioma
Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao A, Woodard GA, Yang H, Malik S. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. Journal Of Thoracic Oncology 2016, 11: 1246-1262. PMID: 27453164, PMCID: PMC5551435, DOI: 10.1016/j.jtho.2016.04.028.Peer-Reviewed Original ResearchConceptsMalignant mesotheliomaOverall survivalHigh mobility group box 1Mobility group box 1Development of MMIncidence of MMGroup box 1Novel therapeutic approachesNational Cancer InstitutePublic health authoritiesU.S. National Cancer InstitutePreventable malignancyStandard chemotherapyCancer CenterBlood biomarkersLung cancerMineral fibersClinical trialsCurrent treatmentOccupational exposureProtein 1 mutationConsensus reportTherapeutic approachesGermline BRCA1Clinical Oncology